ClinicalTrials.gg
TerminatedNCT01195727Updated Apr 7, 2017

Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter

A Phase 1 interventional study of Apixaban in Venous Thromboembolism, sponsored by Bristol-Myers Squibb. Terminated at 14 sites in 5 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-04-07.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Non-randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies testing apixaban in Venous Thromboembolism — 11 open to participants now, 11 under way, 1 of them phase 3. apixaban · Venous Thromboembolism.

Enrollment
35th of 37
13 · median 100
Started
2011
the only one that year
Phase 1
5 of 37
2 open now
Registered
1st of 37
by date
Lead sponsor
3 of 37
Bristol-Myers Squibb

Among the 37 studies testing apixaban in Venous Thromboembolism, this one is the 35th largest by enrollment, is the only one that started in 2011, is one of 5 in phase 1, and was the 1st registered.

Venous Thromboembolism

713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

11 of the 37 studies testing apixaban in Venous Thromboembolism are open now, in 7 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About apixaban

apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing apixaban in Venous Thromboembolism, or all of them as a file.
02

Study summary

CV185-079 is a multiple dose Apixaban Pharmacokinetics/Pharmacodynamics (PK/PD) study in pediatric subjects. The objective of this study is primarily to study the PK/PD of Apixaban in pediatric subjects with a central venous catheter.

03

Conditions studied

  • Venous Thromboembolism
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with chronic stable disease with any type of functioning CVC in the upper or lower venous system (e.g., jugular, subclavian; femoral vein) that is anticipated to remain in the subject for the treatment portion of the study.
  • > 12 to \<18 years of age

Exclusion criteria

Exclusion Criteria:

  • Current or recent (within 3 months of study drug administration) gastrointestinal disease or gastrointestinal surgery that, in the opinion of the investigator and the BMS Medical Monitor, could impact the absorption of the study drug
  • Active bleeding or high risk of bleeding
05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Group 5A - Apixaban (Low Dose)

    Group 5: 12 years to \<18 years; 0.66 mg/m² Oral solution, Oral, Twice A Day (BID), 10 days

    Drug: Apixaban

  • Experimental
    Group 5B - Apixaban (High Dose)

    Group 5: 12 years to \<18 years; 1.32 mg/m² Oral solution, Oral, Twice A Day (BID), 10 days

    Drug: Apixaban

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic (PK): Model-derived population & individual PK parameters (e.g., CL/F, Vc/F, KA) used to estimate steady state Cmax & AUC(TAU), Cmin & Tmax in each subject. Population PK model will be developed using plasma concentration vs time data

    Time frame: Days 1, 2, Day 5, 6 or 7 and Day 11

Secondary outcomes

  1. Evidence of anti-Factor Xa confirmed by analysis of anti-Factor Xa PD analysis

    Time frame: Days 1, 2, Day 5, 6 or 7

07

Study locations

14 sites
  • Children'S Hospital Of Orange County
    Orange, California 92868, United States
  • Saint Peter'S University Hospital
    New Brunswick, New Jersey 08901, United States
  • The Toledo Children'S Hospital
    Toledo, Ohio 43606, United States
  • Penn State Hershey Children'S Hospital
    Hershey, Pennsylvania 17033, United States
  • Local Institution
    Bruxelles, 1020, Belgium
  • Local Institution
    Leuven, 3000, Belgium
  • Local Institution
    Edmonton, Alberta T6G 2B7, Canada
  • Local Institution
    Ottawa, Ontario K1H 8L1, Canada
  • Local Institution
    Mexico City, Distrito Federal 14080, Mexico
  • Local Institution
    Mexico, D. F., Distrito Federal 11000, Mexico
  • Local Institution
    Mexico, Distrito Federal 04530, Mexico
  • Local Institution
    Guadalajara, Jalisco 44340, Mexico
  • Local Institution
    Puebla, 72190, Mexico
  • Local Institution
    Amsterdam, 1105 AZ, Netherlands
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2011 to primary completion in Jun 2012, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2010
First posted
Sep 6, 2010
StartActual
Jul 26, 2011
Primary completionActual
Jun 14, 2012
CompletionActual
Jul 16, 2012
Last update
Apr 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01195727
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Sep 6, 2010
Start date
Jul 26, 2011
Primary completion
Jun 14, 2012
Completion
Jul 16, 2012
Last update
Apr 7, 2017

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion